Zevra Therapeutics Statistics
Total Valuation
ZVRA has a market cap or net worth of $626.58 million. The enterprise value is $432.24 million.
| Market Cap | 626.58M |
| Enterprise Value | 432.24M |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ZVRA has 59.50 million shares outstanding. The number of shares has increased by 8.13% in one year.
| Current Share Class | 59.50M |
| Shares Outstanding | 59.50M |
| Shares Change (YoY) | +8.13% |
| Shares Change (QoQ) | +0.65% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 72.06% |
| Float | 53.87M |
Valuation Ratios
The trailing PE ratio is 8.57 and the forward PE ratio is 10.59.
| PE Ratio | 8.57 |
| Forward PE | 10.59 |
| PS Ratio | 4.25 |
| Forward PS | 3.56 |
| PB Ratio | 2.62 |
| P/TBV Ratio | 2.74 |
| P/FCF Ratio | 16.40 |
| P/OCF Ratio | 16.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.03, with an EV/FCF ratio of 11.32.
| EV / Earnings | 5.78 |
| EV / Sales | 2.93 |
| EV / EBITDA | 9.03 |
| EV / EBIT | 9.32 |
| EV / FCF | 11.32 |
Financial Position
The company has a current ratio of 5.46, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.46 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | 0.03 |
| Interest Coverage | 12.71 |
Financial Efficiency
Return on equity (ROE) is 41.93% and return on invested capital (ROIC) is 90.44%.
| Return on Equity (ROE) | 41.93% |
| Return on Assets (ROA) | 9.96% |
| Return on Invested Capital (ROIC) | 90.44% |
| Return on Capital Employed (ROCE) | 17.08% |
| Weighted Average Cost of Capital (WACC) | 10.18% |
| Revenue Per Employee | $2.42M |
| Profits Per Employee | $1.23M |
| Employee Count | 61 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.04 |
Taxes
In the past 12 months, ZVRA has paid $11.97 million in taxes.
| Income Tax | 11.97M |
| Effective Tax Rate | 13.30% |
Stock Price Statistics
The stock price has increased by +7.56% in the last 52 weeks. The beta is 0.99, so ZVRA's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +7.56% |
| 50-Day Moving Average | 11.07 |
| 200-Day Moving Average | 10.78 |
| Relative Strength Index (RSI) | 49.69 |
| Average Volume (20 Days) | 815,700 |
Short Selling Information
The latest short interest is 6.23 million, so 10.46% of the outstanding shares have been sold short.
| Short Interest | 6.23M |
| Short Previous Month | 7.15M |
| Short % of Shares Out | 10.46% |
| Short % of Float | 11.56% |
| Short Ratio (days to cover) | 6.56 |
Income Statement
In the last 12 months, ZVRA had revenue of $147.76 million and earned $74.97 million in profits. Earnings per share was $1.23.
| Revenue | 147.76M |
| Gross Profit | 141.03M |
| Operating Income | 46.50M |
| Pretax Income | 89.98M |
| Net Income | 74.97M |
| EBITDA | 47.98M |
| EBIT | 46.50M |
| Earnings Per Share (EPS) | $1.23 |
Balance Sheet
The company has $195.57 million in cash and $1.23 million in debt, with a net cash position of $194.34 million or $3.27 per share.
| Cash & Cash Equivalents | 195.57M |
| Total Debt | 1.23M |
| Net Cash | 194.34M |
| Net Cash Per Share | $3.27 |
| Equity (Book Value) | 238.92M |
| Book Value Per Share | 4.02 |
| Working Capital | 184.47M |
Cash Flow
In the last 12 months, operating cash flow was $38.74 million and capital expenditures -$459,000, giving a free cash flow of $38.28 million.
| Operating Cash Flow | 38.74M |
| Capital Expenditures | -459,000 |
| Depreciation & Amortization | 1.47M |
| Net Borrowing | -60.09M |
| Free Cash Flow | 38.28M |
| FCF Per Share | $0.64 |
Margins
Gross margin is 95.44%, with operating and profit margins of 31.47% and 52.80%.
| Gross Margin | 95.44% |
| Operating Margin | 31.47% |
| Pretax Margin | 60.90% |
| Profit Margin | 52.80% |
| EBITDA Margin | 32.47% |
| EBIT Margin | 31.47% |
| FCF Margin | 25.90% |
Dividends & Yields
ZVRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.13% |
| Shareholder Yield | -8.13% |
| Earnings Yield | 11.67% |
| FCF Yield | 6.10% |
Analyst Forecast
The average price target for ZVRA is $25.25, which is 139.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.25 |
| Price Target Difference | 139.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 28.37% |
| EPS Growth Forecast (3Y) | 10.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 28, 2020. It was a reverse split with a ratio of 1:16.
| Last Split Date | Dec 28, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
ZVRA has an Altman Z-Score of 4.91 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.91 |
| Piotroski F-Score | 5 |